Osteoporosis is a condition in which Bones become weak or fragile, and bone density decreases. It is majorly observed in old age people along with this they have back pain, bone fractures, and tooth loss. This degeneration of bone tissue condition mainly occurs due to overproduction of parathyroid hormone. This condition can cause fractures which will be very harmful to the person. Some observable symptoms of this condition are hunched posture (kyphosis), gradual loss of weight, and fractures that occur in minimal trauma or normally in daily activities. For the diagnosis of osteoporosis, doctors mainly go through the medical family history, age, gender, and current medications used by the person. To check the bone density of any person by diagnostic procedures like dual energy absorptiometry, also can-do blood tests to check the level of Calcium and Vitamin D.
Coprescription of calcium and vitamin D is now recommended for the treatment of osteoporosis, and current guidelines advocate that older adults receive at least 800–1000 IU per day of vitamin D along with calcium to reduce the risk of falls. Current NOF guidelines recommend that premenopausal women and men aged 50 years and younger without risk factors for osteoporosis should receive a total of 1000 mg of elemental calcium daily [NOF, 2010]. Postmenopausal women, men older than 50 years, and individuals with risk factors for osteoporosis should receive a total of 1200–1500 mg of calcium daily. Calcium consumed from dietary intake is deemed to be the optimal source but calcium supplements are recommended if dietary sources are inadequate. Treatment of Osteoporosis is done by medications such as Biphosphonates, selective estrogen inhibitor modulator, Calcitonin, and parathyroid hormone therapy. Biphosphonates have dominated the market in huge value and secondly, RANK Ligand inhibitors are anticipated to expand at fasted rate in coming years. According to the Osteoporosis Foundation, it was estimated that out of 1 in 5 men and 1 in 3 women at the age of 50 and after may experience osteoporosis fractures in their remaining life.
Download Your Free PDF Sample: Unlock Key Market Insights @ https://cognizancemarketresearch.com/request/osteoporosis-drug-market/
Global Osteoporosis Drug Market – Competitive Insights
On December 9, 2022, Chugai Pharmaceutical Ltd. and Towa Pharmaceutical Ltd. a Japan-based pharmaceutical company of generic drugs made a partnership deal for the launch of Osteoporosis Drug Edriol Tablet.
On December 6, 2022, Rani Therapeutics announced the topline result from part 2 (repeat dose portion) of RT – 102 Phase I clinical trials The study achieved all the endpoints, and further company anticipated initiating Phase II Clinical Studies of Drug RT – 102
On October 6, 2022, Entera Bio Ltd announced the FDA agreement for Phase III Clinical trials to support an NDA for EB613 for the treatment of Osteoporosis.
Some of the Key Players in the Global Osteoporosis Drug market include –
- Sanofi
- Entera Bio Ltd
- Johnson & Johnson Services, Inc. (U.S.)
- Bayer AG
- AbbVie Inc.
- Allergan
- Amgen Inc.
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceutical Industries Ltd.
- Novo Nordisk A/S (Denmark)
- Cipla Inc. (India)
- GlaxoSmithKline plc.
- F. Hoffmann-La Roche Ltd
- Novartis AG (Switzerland)
- Eli Lilly And Company.
- AstraZeneca
- Pfizer Inc.
- Takeda Pharmaceutical Company Limited.
- Bristol-Myers Squibb Company
Global Osteoporosis Drug Market – Growth Drivers
Day by day prevalence of osteoporosis is increasing as the geriatric population in some countries is increasing. In the majority of cases primary Osteoporosis which occurs in women after menopause due to the sudden decrease of estrogen is the never-ending cause of Osteoporosis. The changing lifestyle, sedentary life, and poor diet have increased the chance of osteoporosis. Improper lifestyle directly leads to a decreased level of Calcium and Vitamin D which are required in Diet. Awareness regarding osteoporosis and future side effects are known by people so earlier people take care of this condition. As a result, more people do diagnosis tests and take treatment for the condition. The rising number of partnerships with companies directly leads to taking the market in high in coming years. As technological development is also increasing more effective and targeted treatments can be made by using technology and knowing the molecular biology, pathophysiology, and genomics of Osteoporosis.
Global Osteoporosis Drug Market – Restraints
The major challenge faced by this market is the side effects caused by Osteoporosis drugs, most of the drugs have potential side effects such as atypical fractures and osteonecrosis. Safety concern has to be taken by the regulatory authorities for the avoidance of such side effects. Most Osteoporosis drugs have patent expirations and when generic versions come to market the price of the drug decreases which directly decreases the Market outcome. High development costs and time taking processes, for the development of any drug, have to be approved by preclinical and clinical trials which is time-consuming. High cost of medicine and after the taking of medication the adverse effects push back the market. COVID-19 has delayed the treatment of many patients who already have Osteoporosis. American Society of Bone and Mineral Research has set up an orthopedic committee to oversee the treatment of Osteoporosis during the COVID-19 Period.
Download Free PDF: Sample Our Market Research @ https://cognizancemarketresearch.com/request/osteoporosis-drug-market/
Global Osteoporosis Drug Market – Opportunities
Personalized treatment approaches have already started in many countries, Targeted therapies have started which will avoid the side effects of taking medication these all improve the effectiveness and safety of the Drug and more acceptable to people. The increasing geriatric population and inadequate lifestyle approach makes this market grow steadily.
The demand for injectable Osteoporosis drugs going to rise in coming years as it does not cause any stomach upset and more easy way to handle the patient itself. Research and Development are going on for the innovations of Targeted therapy and exploring new mechanisms of Action. Day by day pharmaceutical and Healthcare facilities are increasing globally which is another sign of a growing market. In the United States, the Month of May is celebrated as National Osteoporosis Awareness and Prevention Month to boost awareness, by organizing many events like conferences, seminars, and workshops. Supporting Foundation has been started like Bone Health and Osteoporosis Foundation whose motive is to directly and positively impact the lives of Men and women affected by Osteoporosis.
Global Osteoporosis Drug Market – Geographical Insight
The market for dry Osteoporosis Drugs is segmented into regions such as North America, Latin America, Europe, Asia-Pacific, the Middle East & Africa. North America will be going to dominate the Osteoporosis drug market throughout the forecast period due to established infrastructure and the Prevalence of patients. The US has the largest market share due to the growing adult population and more people having Osteoporosis. According to the National Osteoporosis Foundation, it was estimated that more than 10 million people were diagnosed with osteoporosis at year of 2020. The rising expenditure, expansion of the life sciences department, and development of healthcare infrastructure direct the growth of the Osteoporosis market in the Asia Pacific region. Asia Pacific region is large and the rising number of aging populations directly makes expansion of the Osteoporosis market. India is one of the fastest-growing Osteoporosis Markets. In India, more women are suffering from Osteoporosis which results in decreased bone mass and altered bone structure.
Global Osteoporosis Drug Market – Key Development
- On August 27, 2021, Enzene Bioscience Ltd, got marketing authorization from the Drug Controller General of India for its Biosimilar drug DENOSUMAB, indicated for the treatment of Osteoporosis
- On January 18, 2021, the medication Livogiva was introduced to Europe by Theramex, a pharmaceutical company headquartered in London.